$275 Million Settlement in Generic Drug Class Action for Consumers and Payers

Your legal rights might be affected by a proposed $275,000,000 Settlement in a class action lawsuit (In re Generic Pharmaceuticals Antitrust Litigation, No. 16-MD-2724) pending in the United States District Court for the Eastern District of Pennsylvania. The lawsuit claims that Sandoz Inc. and Fougera Pharmaceuticals Inc. (“Sandoz”) and other generic manufacturers (the “Non-Settling Defendants”) violated federal and state antitrust laws, consumer protection statutes, and common law, causing End-Payers – including consumers and Third-Party Payers (“TPPs”) (e.g., entities such as insurers or employers with self-funded prescription drug plans) – to pay more than they should have for certain prescription generic drugs (“Named Generic Drugs”). Sandoz denies that it is liable to End-Payers. The Court has not decided who is right. The lawsuit against the Non-Settling Defendants remains ongoing.

Read more at PR Newswire.